Citigroup Inc Tarsus Pharmaceuticals, Inc. Transaction History

Citigroup Inc

$153 Billion
Q2 2024

A detailed history of Citigroup Inc transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Citigroup Inc holds 15,750 shares of TARS stock, worth $522,112. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,750

Previous 14,122 11.53%

Holding current value

$522,112

Previous $513,000 16.57%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$25.17 - $38.73 $40,976 - $63,052	1,628 Added 11.53%	15,750 $428,000
Q1 2024 May 10, 2024	BUY	$19.61 - $39.22 $42,004 - $84,009	2,142 Added 17.88%	14,122 $513,000
Q4 2023 Feb 09, 2024	BUY	$12.98 - $20.73 $101,633 - $162,315	7,830 Added 188.67%	11,980 $242,000
Q3 2023 Nov 09, 2023	SELL	$14.75 - $24.62 $57,716 - $96,338	-3,913 Reduced 48.53%	4,150 $73,000
Q2 2023 Aug 10, 2023	BUY	$11.57 - $19.63 $84,727 - $143,750	7,323 Added 989.59%	8,063 $145,000
Q1 2023 May 11, 2023	SELL	$11.92 - $16.27 $1,895 - $2,586	-159 Reduced 17.69%	740 $9,000
Q4 2022 Feb 09, 2023	BUY	$14.12 - $18.72 $8,754 - $11,606	620 Added 222.22%	899 $13,000
Q3 2022 Nov 10, 2022	SELL	$14.08 - $18.5 $13,291 - $17,464	-944 Reduced 77.19%	279 $5,000
Q2 2022 Aug 10, 2022	BUY	$11.08 - $19.08 $10,049 - $17,305	907 Added 287.03%	1,223 $18,000
Q1 2022 May 12, 2022	SELL	$14.49 - $24.28 $26,502 - $44,408	-1,829 Reduced 85.27%	316 $5,000
Q4 2021 Feb 10, 2022	BUY	$21.21 - $29.68 $25,091 - $35,111	1,183 Added 122.97%	2,145 $48,000
Q3 2021 Nov 10, 2021	BUY	$21.45 - $29.22 $20,634 - $28,109	962 New	962 $21,000

Others Institutions Holding TARS

# of Institutions

155

Shares Held

40.4M

Call Options Held

37.9K

Put Options Held

808K

View Full List

About Tarsus Pharmaceuticals, Inc.

Ticker TARS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,658,500
Market Cap $884M
Description
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...

More about TARS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account